Oncology

PROTOCOL: CA184 156.

Randomized multi-centre, double blind phase 3 trial to compare the effectiveness of Epilimumab plus Etoposide/Platinumen compared with Etoposide/Platinum in patients with recently diagnosed metastatic small-cell lung cancer (ED-SCLC).

Study Code: CA 184156

Chief Researcher: Gaspar Esquerdo.

Promoted by: Brystol-Myers-Squibb

PROTOCOL: CA 184 124.

Randomized and open phase II clinical trial to evaluate the effectiveness and safety of Ipilimumab versus Pemetrexed in patients with recurrent non-small cell squamous cell lung cancer in phase IV who have not progressed following four cycles of first line platinum-based chemotherapy.

Chief Researcher: Gaspar Esquerdo.

Promoted by: Brystol-Myers-Squibb

PROTOCOL: TS-PO4832.

Phase III, multi-centre, randomized, double-blind Study with active control to evaluate the safety and effectiveness of Rolapitant in preventing nausea and vomiting induced by chemotherapy (CINV) in patients receiving highly emetic chemotherapy (HEC).

Chief Researcher: Gaspar Esquerdo

Promoted by: Pharm-Olam

PROTOCOL: TS-PO4833.

Chief Researcher: Gaspar Esquerdo

Promoted by: Pharm-Olam

PROTOCOL: TS-PO4834.

Phase 3 randomized multi-centre double blind study with active control to evaluate the safety and effectiveness of Rolapitant in preventing nausea and vomiting induced by moderately emetic chemotherapy (MEC)

Chief Researcher: Gaspar Esquerdo.

Promoted by: Pharm-Olam

PROTOCOL: CTK1258A2302

Titled: Phase 3, multi-centre, open and randomized study to compare the safety and effectiveness of TK1258, as opposed to Sorafenib in patients with metastatic renal cell cancer following failure of antiangiogenic (mTOR inhibitor and targeted on the VEGF).

Chief Researcher: José Manuel Cervera Grau.

Promoted by: Novartis Farmacéutica, S.A

IN PROGRESS

PROTOCOL: BEN-ABI 01.2012.

Compassionate use of Abiraterone in castration resistant prostate cancer in patients unsuitable for chemotherapy with Taxotere. A retroactive and prospective EPA-OD.SP study.

Chief Researcher: José Manuel Cervera Grau.

Promoted by: HCB

COMPLETED

PROTOCOL: CABAZ06092 (CAPRISTANA)

Prospective observational study to discover the usefulness of Cabazitaxel combined with oral prednisone (prednisolone) in regular clinical treatment of patients with hormone-resistant metastatic prostate cancer.

Chief Researcher: José Manuel Cervera

 

Neurology

PROTOCOL: BEN-ICT-01-2012. ACUTE STROKE METABOLOMICS.

Chief Researcher: Francisco Mira Berenguer.